---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007256"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:18:03.044140+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive

## Summary
- Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.
- Revenue fell to $0.5M from $1.3M due to lower Alnylam ONPATTRO royalties.
- Cash, equivalents and marketable securities $93.7M at Sep 30, 2025, down from $122.6M at Dec 31, 2024.
- Moderna US trial set for March 2026; Pfizer-BioNTech claim construction ruling favorable in Sep 2025.
- Imdusiran: 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up off treatment up to 2+ years.

## SEC filing metadata
- accession: 0001171843-25-007256
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/0001171843-25-007256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/f8k_111325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007256
- JSON: https://secwatch.observer/filing/0001171843-25-007256.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.